Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

Cancer Cell. 2020 Mar 16;37(3):420. doi: 10.1016/j.ccell.2020.03.003.
No abstract available

Publication types

  • Published Erratum